BeOne Medicines
Xiaobin Wu currently serves as the Global President and Chief Operating Officer at BeiGene, a position held since May 2018. Prior experience includes serving as Regional President for Essential Health in Greater China and President and Managing Director for China and Hong Kong at Pfizer from January 2004 to April 2018, following the acquisition of Wyeth Pharmaceuticals. Xiaobin Wu also held the role of General Manager for Bayer in China from January 2001 to January 2004. Educational qualifications include a Doctor of Philosophy (PhD) in Biochemistry and Pharmacology and a Master's degree in Molecular Biology, both from the University of Konstanz.
BeOne Medicines
34 followers
BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.